ModifiedUnitedHealthcarePolicy N/A

Chelation Therapy for Non-Overload Conditions

Defines UnitedHealthcare's coverage rationale, evidence review, and state-specific application for chelation therapy in non-overload conditions (e.g., cardiovascular disease, autism, environmental heavy metal exposure) and clarifies that chelation for heavy metal toxicity/overload (iron, copper, lead, aluminum) is proven and medically necessary but is not addressed in detail in this policy.

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy for Non-Overload Conditions

Policy CodePolicy N/A

Change TypeTitle and coverage rationale revised

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionWhen deciding coverage, providers must reference federal, state or contractual requirements for benefit plan coverage as those govern if they differ from this standard policy.

POLICY UPDATE CHANGES

Title changed from 'Chelation Therapy for Non-Overload Conditions' to the current title and coverage rationale language was updated.

Updated Clinical Evidence and References sections to reflect current information.

Application Kentucky and Louisiana updated reference links for state-specific policy version.

Archived previous policy version CS016.N.

MultipleEvidence cited

1Material policy coverage change

Coverage Summary

This part defines UnitedHealthcare's coverage rationale, evidence review, and state-specific application for chelation therapy in non-overload conditions and clarifies policy-level statements about chelation. It specifically notes that chelation for heavy metal toxicity/overload (e.g., iron, copper, lead, aluminum) is proven and medically necessary. Policy statements and applicability also emphasize that this document addresses chelation for non-overload conditions and that federal, state, or contractual requirements govern when they differ from this standard policy.

Effective date: 08/01/2025. Last review: 09/01/2025.

Key policy dates and status

Effective DateAugust 1, 2025

Last ReviewSeptember 1, 2025

Policy StatusMODIFIED

Material Policy Changetrue - Replaced prior language to state that chelation for heavy metal toxicity/overload is proven and medically necessary

Page ReferenceThis part includes pages 10-12 of 12

Medical-Necessity Criteria

Coverage Rationale (policy-level statements reflected in revision history)

Policy statements and applicability:

ALL of the following

Chelation therapy for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary.
This policy addresses chelation therapy for non-overload conditions; coverage decisions must reference federal, state or contractual requirements which may differ and govern in the event of conflict.

refARRAYITEMERROR_REPLACE_WITH_ref_FIELD_b1_0_xxx_ref_b1_0_1b1_0_2b1_0_3_b1_0_4_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0_ref_b1_0

refOrigErrFix_me_replace_with_ref_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0_b1_0

refOrigErr_replace_with_ref_b1_0_final_fix_b1_0_note_do_not_use_this_field_b1_0_ref_b1_0_final_fix_backref_removed_b1_0_REF_b1_0_REPLACED_WITH_b1_0_field_in_final_output_b1_0_ref_b1_0_fixed_okAY_b1_0_ref_b1_0_final_done_b1_0_ref_b1_0_final

Provider Actions

Documentation Required

Reference contractual and regulatory requirements

When deciding coverage, providers must reference federal, state or contractual requirements for benefit plan coverage as those govern if they differ from this standard policy.

Prior Authorization

Prior authorization and tools

UnitedHealthcare may use external tools (e.g., InterQual criteria) to assist in administering benefits and coverage determination for chelation therapy.

Note: External decision-support tools such as InterQual may be used to assist benefit administration and prior authorization determinations.

Evidence and Guidelines

Background: This document is Part Two of a UnitedHealthcare medical policy on chelation therapy and contains references and policy history. The revision includes a substantive wording change clarifying that chelation for heavy metal toxicity and overload conditions is now stated as proven and medically necessary, replacing prior language that had not addressed those conditions in detail.

Study / Guideline	Notes
Guidelines
AHA/ACC and other society guidelines cited (2023 AHA/ACC chronic coronary disease guideline; 2014 ACC/AHA focused update) and related society statements noting chelation is not approved for CVD prevention (Fihn et al. 2014; Virani et al. 2023).

Revision History

08/01/2025revisedLatest

is_material: Replaced language indicating chelation for heavy metal toxicity and overload conditions was not addressed in this policy with statement that such chelation is proven and medically necessary. Title changed from 'Chelation Therapy for Non-Overload Conditions' to the current title and coverage rationale language was updated.

08/01/2025clarified

Updated Clinical Evidence and References sections to reflect current information, including recent trials and guideline citations (e.g., TACT, TACT2, JAMA 2013/2024; 2023 AHA/ACC guideline).

09/01/2025added

State-specific application links updated: Kentucky and Louisiana application reference links updated to reflect current title for state-specific policy version.

08/01/2025removed

Prior version archived: Archived previous policy version CS016.N.

References and Policy Notes

Page reference: This part includes pages 10-12 of 12 and is Part 2 of the policy. Updated references cited in this section include the original TACT trial (JAMA 2013) and the TACT2 randomized clinical trial (JAMA 2024), related publications and guideline citations through 2023–2025 as reflected in the References and Policy History sections. This is a contextual citation note only; the evidence table and trial details are included elsewhere in the policy.

Quick facts / stats

Evidence citedMultiple recent randomized trials and guideline citations

Material policy coverage change1